Open | 0.75 |
Previous Close | 0.754 |
Day Range | 0.70 - 0.76 |
52-Week Range | 0.70 - 7.20 |
All-Time High | 124,100.00 |
Avg. Volume (50-day) | 253,862.36 |
EPS (TTM) | -7.4180 |
Next Earnings Date | 2024-03-28 |
Last Earnings Date | 2023-11-09 |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.0900 |
PEG Ratio | - |
Price to Book | 0.67 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | - |
Revenue per Share (TTM) | - |
Shares Outstanding | 1.746 M |
Share Float (%) | 1.71 M |
% Held by Institutions | 0.42 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 0.96 (-27.08%) |
+/- SMA(50) | 1.47 (-52.38%) |
+/- SMA(200) | 1.77 (-60.45%) |
5-Day Perf. | -26.32% |
1-Month Perf. | -35.19% |
3-Month Perf. | -61.96% |
6-Month Perf. | -53.02% |
YTD Perf. | -61.96% |
1-Year Perf. | -82.29% |
RSI(14) | 29.14 |
ATR(14) | 0.12 |
ADX(14) | 11.04 |
Beta (5Y) | 0.79 |
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
SLRX has triggered the following predefined scans:
No Recent Scan Appearances |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.